Anti-HER3 Antibodies May Inhibit Growth of Tumors Harboring NRG1 Fusions

home / between-the-lines / between-the-lines-the-anti-her3-mab-seribantumab-effectively-inhibits-growth-of-patient-derived-

In this program, D. Ross Camidge, MD, PhD, and Alexander Spira, MD, PhD, discuss a recently published paper on the anti-HER3 monoclonal antibody seribantumab in the treatment of tumor samples with oncogenic NRG1 fusions.

Thoracic Oncology Specialists

EP. 1: Use of the Anti-HER3 Antibody Seribantumab in Preclinical Models

D. Ross Camidge, MD, PhD;Alexander Spira, MD, PhD, FACP
August 20th 2021

Experts review a preclinical study of the anti-HER3 monoclonal antibody seribantumab, used in cell lines and mouse models of solid tumors.

Thoracic Oncology Specialists

EP. 2: Potential Translational Relevance of Preclinical Findings With Seribantumab

D. Ross Camidge, MD, PhD;Alexander Spira, MD, PhD, FACP
August 26th 2021

Thoracic oncologists discuss key takeaways and potential translational relevance of seribantumab based on a recent publication by Igor Odintsov, MD, and colleagues.